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INTRODUCTION 
 
 Human parturition has been termed ‘labour’ in recognition of the hard 
work that the parturient as well as the uterine myometrium have to perform in 
order to deliver the fetus. Labour refers to the onset of effective uterine 
contractions leading to progressive effacement and dilatation of the cervix 
resulting in the expulsion of the fetus, placenta and the membranes.1 
 
 According to Turnbull (1976)- “The spontaneous onset of labour is a 
robust and effective mechanism…. And should be given to operate on its 
own.  We should only induce labour when we are sure that we can do 
better” 
 
 The most important decision to be made when considering induction of 
labour is whether or not the induction is justified.  How it is to be achieved, is 
a secondary decision.  Whatever method is chosen to implement a justified 
decision to induce labour, uterine contractility and maternal and fetal 
wellbeing should be monitored closely. 
 
 In the present world, there is a spectrum of valid indications for 
induction of labour.  The concept of elective induction for the convenience of 
the obstetrician and the patient, is not recommended by the ACOG at present, 
but this practice is recommended or indicated when the benefits for the 
mother and fetus outweigh those of continuing the pregnancy and to achieve 
vaginal delivery, thus avoiding an unnecessary caesarean section2. 
 
 The present day obstetrics, calls for induction for a myriad of 
obstetrical, medical and fetal indications, that include valid indications which 
include emergency situations like premature rupture of membranes with 
chorioamnionitis, severe preeclampsia etc., to several relative indications 
which may amount to or approximate an elective induction such as a 
residence at an appreciable distance from an obstetric facility or history of 
rapid labour in the previous pregnancy3 . 
  
 Compromise to maternal longevity, accounts for the majority of 
indications for induction of labour, while the wide diversity of fetal 
indications are most often not compromising to their survival or morbidity. 
Favourability of the cervix is a need for labour induction.  Research in this 
direction has helped in the development of various methods to ‘ripen’ the 
cervix prior to uterine contractions.  The discovery of prostaglandins, and 
lately the antiprogesterones, have made labour induction at the disposal of the 
obstetrician, enabling the delivery of the patient as and when required, thus 
allowing a carefully planned active management, and in bringing down the 
trauma of a prolonged or protracted and painful labour for the patient, to give 
her a healthy baby without compromising her health.  
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AIMS OF THE STUDY 
 
 
1. To compare the efficacy and safety of oral mifepristone, and 
endocervical PGE2 gel for preinduction cervical ripening in term 
pregnancies and prolonged pregnancies. 
 
2. To evaluate the effect of these drugs on parturition and neonatal 
outcome. 
 
3. To critically evaluate the effect of these drugs on primigravida and 
multigravida. 
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Induction of labour: 
 
 Induction of labour is one of the most commonly performed 
interventions in modern obstetrics with upto 20% of pregnant women having 
labour induced in some countries. 
 
 Induction can be defined as an intervention intended to artificially 
initiate uterine contractions resulting in the progressive effacement and 
dilatation of the cervix which will result in the birth of the baby by vaginal 
route. 
 
 Induction rates have been influenced by several reports worldwide, 
which claimed that an active induction policy, led to substantial reduction in 
perinatal and maternal morbidity and mortality. 
 
 The incidence of induction of labour varies widely in different parts of 
the world.  It is 10-15% in developing countries and 10-25% in the developed 
world.  At Parkland Hospital, approximately 30% of labour were induced or 
augmented using oxytocin.   
 
 
 
History of Induction of Labour: 
 
History of labour induction, antedates back over the past three to four 
centuries, which has been accomplished by an innumerable number of 
mechanical and pharmacological methods.  This exhaustive list is enumerated 
below. 
 
I. Mechanical Methods: 
 
1. Amniotomy or artificial rupture of memberanes or the ENGLISH 
METHOD was the first really effective method of induction of labour, 
practised by Thomas Denman in 1756. Scheel’s method 
2. Electricity for labour induction (Herder 1802, Schreiver 1843, 
Renford 1842, Henning 1856, Theobald 1973) 
3. Stripping or sweeping of membranes by using the forefinger 
(Hamilton 1810) 
4. Massage of the uterus (Uslamer and d’Outrepont 1820) 
5. Massage of the breasts (Friedricgh 1939) 
6. Sponge tents in the cervix (Brunninghousen 1820) 
7. Instrumental dilatation of the cervix has been an age-old method. 
8. Vaginal tampoons (Scholler 1842) 
9.  Cervical tampoons (Kehrer 1888) 
10. Extraamniotic injection of fluid or the COHEN’S METHOD 
(1846) or Glycerin (Pelzer 1891) and Artes’ Paste. 
11. Introduction of a catheter or the KRAUS’ METHOD (Moir 1855) 
12. Hot vaginal  douche (Kinisch 1856) 
13. Hot carbolic douche (Scanzoni 1856) 
14. Rubber bags in the cervix (Barnes 1861) 
15. Matreurynter (Tarnier 1862), small rubber balloons made of pig’s 
bladder. 
16. Hygroscopic cervical dilators (Kramner 1995, Gilson 1996) 
17. Laminaria tent (Wilson 1865) 
18. Balloon catheter for cervical dilatation (Baners and Woodman 1863) 
19. Paracentesis of amniotic fluid usually with injection of irritant 
solutions 
20. Extra amniotic saline infusion – EASI (Schreyer 1989) 
 
II. Pharmacological Methods: 
 
1. Oxytocin was the first polypeptide hormone synthesized, which was an 
important milestone in labour induction.  Its discovery won a Nobel prize 
for Du Vigneaud in 1953 and the efforts of Turnbull and Anderson (1968) 
led to its acceptance in routine obstetric practice. 
 
However, it was noted that this method of induction resulted in more 
postpartum hemorrhage than induction with prostaglandins (Howarts and 
Botha 2001).  When compared to induction with prostaglandins, evidence 
suggests that oxytocin induction is associated with a lower chance of 
delivery within 24 hours; there was no difference in the rate of cesarean 
section.  However, subgroup analysis reveals more information showing 
that:  
 In primigravid women, there is a reduction in the number of women 
satisfied with the method of induction when oxytocin is used.  
 
 In women with an unfavorable cervix, that oxytocin induction is 
associated with a higher rate of cesarean section 
 
 In women with a favorable cervix, induction with oxytocin was 
associated with greater satisfaction.  
 
2. The discovery of Prostaglandins in the 1930’s from human semen and its 
elucidation in the biological role in the parturition process, has 
revolutionized the process of labour induction and has been the greatest 
armamentorium in the induction of labour for the present day obstetrician.  
 
Prostaglandins are autocoids detected in almost all tissues and body 
fluids including lungs, heart, stomach, adrenals, liver, spleen, kidney, central 
nervous system, uterus, vesical gland and seminal fluid.  Named by Von 
Euler of Sweden in 1935, who extracted it from the seminal vesicle. Sune 
Bergstrom of Sweden received a Nobel Prize for its synthesis in 1932. 
 
 Most protocols recommend the use of intracervical prostaglandin in 
women with an unfavourable cervix and intact membranes; however, there 
are benefits in giving prostaglandin to all women undergoing induction 
regardless of cervical score.  Meta-analysis by the Clinical Effectiveness 
Support Group at the Royal College of Obstetricians and Gynecologists 
showed improved rates of successful vaginal delivery, lower rates of cesarean 
section and higher levels of maternal satisfaction in women induced with 
prostaglandin compared to oxytocin.  However, amniotomy and oxytocin 
infusion are effective in women with a favourable cervix and in areas where 
resources are limited, the cheapness of this method may outweigh the 
consideration of maternal satisfaction.  Vaginal PGE2 tablets appear to be as 
effective as gel formulations and their use may offer financial savings. In 
1992 FDA approved PGE2 (0.5mg intracervically) for cervical ripening and 
labour induction.  
 
 Misoprostol is a synthetic analogue of prostaglandin E1 and is less 
expensive, more stable and easier to store than PGE2.  These factors have led 
to the suggestion that misoprostol will allow the use of prostaglandin for 
induction in areas of the world that have previously been unable to afford this 
luxury (E1 Refaey and Jauniaux 1997).  In the UK and the USA, the drug 
currently has a licence for the treatment of peptic ulceration but has no 
licence for the induction of labour28.  Although the manufacturers have 
indicated that they do not intend to pursue licensing for this purpose, the 
American College of Obstetricians and Gynecologists has issued statements 
that misoprostol is a safe and effective drug for the induction of labour when 
appropriately used (ACOG 1999, 2000)2.  In the UK the Royal College of 
Obstetricians has remained more cautious, agreeing that misoprostol is a 
cheap and effective agent for inducing labour but due to safety concerns, feel 
that further clinical trials are required prior to recommending it’s use in 
general obstetric practice (RCOG 2001a). 
 
3. Mifepristone or RU 486, an antiprogesterone is a receptor level 
antagonist, licensed in the U.K in July 1991.  Mifepristone is a 19-nor-
steroid with a great affinity for the progesterone receptor and thus blocks 
the action of progesterone at a cellular level.  As a fall in the level of 
progesterone is considered one of the important events in the onset of 
spontaneous labour, it therefore seems likely that this drug may be useful 
in induction4.  A number of studies have looked at the efficacy of 
mifepristone in cervical ripening.  When compared to placebo, 200mg oral 
mifepristone increases the chances of spontaneous labour and reduces the 
need for prostaglandins (Lelaidier et al 1993)18.  There is a reduction in 
the induction delivery interval when induction is performed after 
mifepristone and a trend to a reduction in the rate of cesarean section 
(Wing et al 2000)17. 
 These studies in recent literature over the last two decades, shows the 
efficacy of mifepristone not only in first and second trimester induced 
medical abortions, but also its use of late, as a safe, orally effective cervical 
ripening and labour inducing agent. 
 
Other Therapeutic Agents: 
Purified Porcine Ovarian Relaxin (1-4mg) 
 
 Relaxin has been used both vaginally and intracervically to induce 
labour but studies have failed to show any benefit compared to prostaglandin 
(Kelly 2002b)1. 
 
Hyaluronidase 
 
 Hyaluronidase given by cervical injection has been postulated to 
increase cervical softening by increasing tissue water content.  The problems 
associated with its administration and the lack of evidence of any benefit 
associated with using it, is such that its use cannot be recommended.1 
 
Estradiol 
 Estradiol in tylose gel is not commonly used as an induction agent but 
has been used previously in the belief that they may stimulate prostaglandin 
release.  There is no evidence to confirm or refuse their efficacy and their use 
is therefore of historical interest only. 
Indications for Induction of Labour 
 The indications for induction of labour are, where the benefits of 
delivering the fetus at a specified point of time, outweighs the benefits of 
allowing the pregnancy to continue. 
 
 There are two main types of induction, namely Indicated Induction and 
Elective induction. 
A.Indicated Induction 3 
Commonly accepted indications  
• Pregnancy induced hypertension  
• Prelabour rupture of membranes  
• Chorioamnionitis  
• Severe intrauterine growth restriction  
• Isoimmunization  
• Maternal medical problems 
Diabetes mellitus  
Renal disease 
Lupus  
• Fetal demise  
• Prolonged pregnancy  
• Oligohydramnios 
B. Elective induction  
Logistic factors such as distance from the hospital or a history of rapid 
labor and delivery, may be reasonable indications. But elective induction 
(without medical  or obstetric indications ) is generally not recommended.  
 
Contra indications 
1. When vaginal delivery is contraindicated-  
(a) Major degrees of cephalo pelvic disproportion  
(b) Previous VVF repair 
 (c) Pelvic tumour  
(d) Carcinoma cervix  
(e) Previous uterine surgery disruption  
(f) Active gential herpes infection.  
2. Malpresentations. 
3. Placental abnormalities like Vasa praevia and Type III and IV placenta 
praevia. 
4. Appreciable macrosomia  
5. Severe hydrocephalus  
6. Non reassuring fetal heart rate 
Outcome of Induction 
Factors influencing the outcome of induction 
 The process of prelabour cervical softening and dilatation is a part of a 
continuum, which culminates in spontaneous labour. 
 
 The success of any method of induction depends largely on (1) Parity 
and (2) The state of cervix at the beginning of induction.  In most centers, the 
modified Bishop score (1964) is used to assess the favourability of the cervix 
both prior to and following induction.5 The partogram aids in assessing the 
progess of labour. 
 
 Some definitions, useful for assessing the success or failure of 
induction are enlisted below. 
 
Successful induction 
 
 Successful induction is defined as (“Vaginal delivery of an infant in 
good condition with minimum maternal discomfort and side effects, 
within a specified framework of time”). 
Failed induction 
 
 Defined by Duff et al (1984), (as the failure to enter the active phase 
of labour, after twelve hours of regular uterine contractions).  Failed 
induction, is diagnosed when, a patient who was induced, does not deliver 
vaginally, in the absence of fetal distress, with acute events like abruption or 
cord prolapse and failure of progress due to cephalopelvic disproportion or 
malposition and or if the patient has not entered the active phase of labour 
despite adequate management for twelve hours (Arulkumaran et al 1985). 
  
Methods of Induction 
 
 There are only three existing broad approaches in induction of labour 
practiced in the current obstetric practise.  They are: 
 
(A) Amniotomy or Artificial rupture of membranes 
(B) Use of oxytocic agents 
(C) Stripping of membranes or Sweeping of membranes. 
 
(A) Amniotomy or Artificial rupture of membranes 
Introduced by Thomas Denman more than 200 years ago, the 
procedure represents one of the most irrevocable interventions in pregnancy, 
and more than any other procedure calls for a firm commitment to delivery 
within a short time scale to avoid the risk of maternal and fetal infection. 
Amniotomy alone often results in vaginal delivery in most women with 
good cervical score.  However Patterson in 1971 found that 15% of 
primigravidas and 22% of multigravidas were not in established labour more 
than 24 hours after amniotomy.  Therefore in current obstetric practice, 
amniotomy is usually combined with oxytocin immediately or after a variable 
interval. After controlled artificial rupture of membranes without dislodging 
the presenting part amniotic fluid is allowed to drain, color of liquor and any 
cord prolapse is noted. 
 
 There are two types of rupture of membranes – Low rupture of 
membranes (LARM) done by using a kocher’s artery forceps and high 
rupture of membranes or hind water amniotomy done by using a Drew- 
Smythe catheter.  The low rupture of membranes is the basic procedure in 
induction of labour. 
 
Prerequisites 
• Vertex presentation  
• Cervix must be well applied to the presenting part  
• High Bishop score  
• No cephalopelvic disproportion. 
 
Mechanism of action 
1. Releases endogenous prostaglandin and may result in labour. 
2. Intrauterinespace decreases progressively following amniotomy so that 
the uterine muscles contract more efficiently. 
 
 
Complications 
Are mainly in the form of infection, chorioamnionitis, cord prolapse, 
premature separation of placenta, injury to the fetus and cervix constant 
drainage of liquor amni, fetal anaemia due to unrecognized vasa previa, risk 
for Rh iso-immunisation. 
 
(B) Stripping of membranes or Sweeping of membranes 
 
Sweeping or stripping of the membranes is an old method of inducing 
labour described by Hamilton in 1810.  Sweeping of the membranes involve 
the digital separation of the membranes from the lower segment and has been 
widely used for many years in the belief that it reduces the need for formal 
induction of labour.  The procedure of membrane sweeping causes an 
increase in the levels of prostaglandin F2alpha (McColgin et al 1993).  
Several recent studies have addressed the validity of this belief and the risks 
associated with this procedure. 
 
In a randomized study of 195 women beyond 40 weeks, two-thirds of 
women undergoing membrane sweeping laboured spontaneously within 72 
hours compared to one-third of women in the control group (Allot and Palmer 
1993).  A recent meta-analysis concluded that sweeping membranes prior to 
term (38-40 weeks) does reduce the frequency of prolonged pregnancy and 
reduce the need for formal induction of labour from 36 per cent to 21 per cent 
(Boulvain et al 2001).  The same review found no evidence of serious 
maternal or neonatal morbidity, such as infection associated with the 
procedure. 
 
Technically, membrane sweeping is not possible in all women 
(Cammu and Haitsma 1998), usually requiring a cervical score greater than 4. 
Women undergoing membrane sweeping, more frequently describe 
discomfort during the vaginal examination, vaginal bleeding and contractions 
not associated with the onset of labour than women not undergoing sweeping 
(Boulvain et al 1999).  This discomfort will not be tolerated by all women 
and counselling prior to membrane sweeping is needed. 
 
Although it is presumed to be a formal method of induction, it is still 
employed by some obstetricians at term, especially when the indications for 
induction are not strong enough.  The forewater is stripped by a gloved index 
finger passed through the cervical canal.  Uterine contractions are frequently 
established following the procedure resulting from the release of endogenous 
prostaglandins, and labour is brought about within 3 days. 
 
3. Oxytocin 
Commonly used method of induction. 
CERVICAL RIPENING 
 
 Cervical ripening is a process by which the cervix becomes soft, 
compliant and partially dilated.  It is due to a combination of biochemical, 
endocrine, mechanical and possibly inflammatory events. 
 
 Cervix is composed of collagen, smooth muscle and connective tissue 
‘ground substance’ containing glycosaminoglycans.  Cervix is predominantly 
composed of types I (66%) and type III (33%).  The firmness of the cervix in 
the non pregnant state is mainly due to the properties of these collagen fibrils 
which are bound together in the form of bundles.  These bundles in turn are 
embeded in ground substance consisting of proteoglycans.7 
 
 In the cervix the main glycosaminoglycan are dermatan sulphate and 
chondroitin sulphate both of which are highly negatively charged and 
hydrophobic.  Hence they repel water and are responsible for the firmness of 
the cervix.  Towards term the glycosaminoglycan concentration of the cervix 
alters and the dermatan and chondroitin sulphates are replaced by hyaluronic 
acid. Hyaluronic acid is hydrophilic and imbibes water. Accumulation of 
water within the substance of the cervix destabilizes the collagen fibrils 
contributing to cervical ripening.  The water content of human cervix 
increases from 80% in non pregnant state to 86% in late pregnancy.1 
 
 Collagenase is an enzyme that breaks down collagen types I, II and III 
and is produced by fibroblasts and leucocytes.  Leucocyte elastase is another 
enzyme that that can break down elastin, collagen and proteoglycans.  It is 
produced by macrophages, neutrophils and eosinoplils.  The levels of both 
these enzymes are found to increase with advancing gestation and are 
associated with progressive decline in the concentration of cervical collagen. 
 
 Cervical remodelling takes place with advancing gestation.  The 
mature collagen, which has many crosslinks that are responsible for its tensile 
strength, is replaced by an immature collagen, which has few such crosslinks.  
Functionally the newly formed immature collagen is much weaker and is 
easily broken down during labour. 
 
Cervical Ripening Methods3 
Mechanical Methods: 
¾ Foley Catheter 
¾ Laminaria tents 
¾ Hygroscopic dilators 
¾ Acupuncture 
¾ Membrane stripping 
 
 
 
Pharmacologic Methods 
¾ Mifepristone (RU 486) 
¾ Dinoprostone (PGE2) 
¾ Misoprostol (PGE1) 
¾ Nitricoxide 
¾ Relaxin 
 
Methods to assess cervical ripening 
¾ Bishop score  
¾ Lange score 
 
Bishop Score 
 
Parameters 0 1 2 3 
Dilatation of cervix (cm) 0 1-2 3-4 5-6 
Effacement of cervix (%) 0-30 40-50 60-70 80 
Consistency of cervix Firm Medium Soft - 
Position of Cervix Posterior Mid Anterior - 
Station -3 -2 -1,0 +1,+2 
 
MIFEPRISTONE (RU 486) 
Introduction: 
 
Mifepristone, a synthetic steroid was discovered in 1980 by Dr. 
Etienne – Emile Beaulieu of France.  Mifepristone is an antiprogestin.  There 
are two types of antiprogestin  
• Type I -RU486, ZK 112993  
• Type II – ZK 98299. 
Structure: 
 
 
 
 
 
Mifepristone is a 19 nor steroid, chemically referred to as 11 beta-(4-
dimethyl amino phenyl)-4, 9-dien-3-one.  It is an antiprogestrone.  It has a 
molecular formula of C19H35NO26.  Its molecular weight is about 429.6.  
The dimethyl amino phenyl side chain at position 11, which is a hydrophilic 
moiety, appears to be essential for the antiprogestronic activity.  It also has 
antiglucocorticoid and antiandrogen activity.  
 
The structure of the gene encoding both isoforms (PRA and PRB) of the 
progesterone receptor includes the location of the n-terminal initiation codon 
for each isoform (AUGB and AUGA)8. The basic structure of this gene is 
shared by all members of the steroid, thyroid, vitamin D, retinoic acid and 
orphan receptor superfamily, with five functional domains: an n-terminal 
transactivation domain (A/B), a DNA-binding domain (C), a hinge region (D) 
and a hormone-binding domain (E).  Regions important for heat shock 
protein binding (HSP), nuclear translocation (NTS) and transcriptional 
activation (TAF-I, -II) are also indicated.2 
 
Mifepristone acts as a competitive receptor antagonist at the 
progesterone receptor in the presence of progesterone and acts as partial 
agonist in the absence of progesterone. Mifepristone at doses greater or equal 
to 1mg/kg antagonize the endometrial and myometrial effects of 
progesterone. Antiglucocorticoid effect of mifepristone is manifested at doses 
greater or equal to 5.5mg/kg and antiandrogenic effect in animals is seen with 
prolonged administration of very high doses of 10-100mg/kg24 
 
 
 III. Receptor binding 
Progesterone receptor schematic diagram. 
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  (1)         (2)        (3) 
 
 
1. Transactivation domain 
2. DNA binding domain 
3. Hormone binding domain 
  
The anti progestin action of mifepristone is mediated by the PR, a 
ligand activated transcription factor with domains for DNA binding, hormone 
binding and transactivation.  The amino acid glycine at position 722, which is 
in the hormone-binding domain of the human PR, appears to be critical for 
mifepristone binding and action.  Substitution of glycine with cysteine in the 
human PR generates a receptor that no longer binds mifepristone. 
 
 
 
 
 
 
 
 Mechanism of action 
 Progesterone and mifepristone produce a conformational change in the 
form of the PR that permits it to bind to DNA. 
Agonist (Progesterone) 
 
Antagonist (mifepristone) 
 
       PR – Progesterone receptor 
                                      HSP – Heat shock protein 
 
 In the absence of ligand the progesterone receptor is associated with 
heat shock proteins.  Binding of progesterone or mifepristone induces 
conformational changes resulting in dissociation of HSP and dimerization of 
PR. The PR complex binds to specific progesterone response elements in the 
promoter regions of progesterone responsive genes. Progesterone – PR 
complex is transcriptionally active resulting in agonistic effects whereas 
mifepristone – PR complex is not transcriptionally active resulting in 
antagonistic effects39. 
 
 Under certain circumstances as in the absence of progesterone, 
mifepristone display progesterone agonistic activity It is related to the 
existence of two isoforms of PR, PR-A and PR-B.  PR-B behaves as a partial 
agonist in the presence of mifepristone.  When PR-A and PR-B are present 
together the antagonistic effects of PR-A can override the agonistic effects of 
PR-B. So agonistic or antagonistic action depends on relative expression of 
PR-A and PR-B in target tissues. 
 
Pharmaco Kinetics  
 Mifepristone is administered orally and is readily absorbed. 
Metabolism in splanchnic circulation reduces its bioavailability to 40%.  
Metabolic clearance rate is 0.55l/kg / day.  It doesnot bind to cortisol binding 
globulin or sex steroid binding globulin31. 
 
 Serum mifepristone levels reached a maximum in one hour after oral 
administration of single dose ranging from 50 to 800mg. After single dose of 
100mg or less the disappearance of mifepristone follows first order kinetics 
with a half life of 20-25 hours.  After higher doses 200-800mg there is an 
initial redistribution phase of 6-10 hours followed by a plateau in serum 
levels for 24 hours or more. 
 
 The major excretory pathway is fecal with less then 10% being 
recovered in urine.  Metabolism involves two step demethylation and 
hydroxylation. Mifepristone metabolite cross the placental barrier during the 
second trimester, the efficacy of placental transfer decreases with advancing 
pregnancy.23 
 
Clinical pharmacology: 
Pregnant uterus  
 Mifepristone acts on receptors in decidua resulting in progesterone 
withdrawal to endometrium, disruption of placental function and uterine 
bleeding. Mifepristione stimulate release of PGEF2α.33,46,47  The increase in 
prostaglandin is due to marked reduction in the activity and tissue 
concentration of prostaglandin dehydrogenase, the key enzyme involved in 
the control of prostaglandin catabolism by mifepristone21. 
 
 Mifepristone increases the sensitivity of the myometrium to prosta 
glandin due to increase in number of gap junctions so that synchronization of 
uterine muscle contractility occurs.  This causes enhanced electrical activity 
resulting in opening of voltage dependent calcium channels, which causes 
calcium influx and thereby muscle contraction.53 
Mifepristone causes cervical ripening in women undergoing 
termination of pregnancy. Mifepristone causes cervical ripening directly or 
through the blockage of progesterone receptors49. Mifepristone stimulates the 
release of nitric oxide and the expression of inducible nitric oxide synthase in 
cervical cells of women. This is one of the mechanism by which mifepristone 
initiates cervical ripening52.  
 
Other Uses 
1. Termination of early pregnancy  
Medication abortion became an option for early abortion in India when 
in April 2002, the Drugs Controller General approved the use of mifepristone 
to terminate early pregnancies.  
 
In December 2006, the Drugs Controller General of India granted the 
permission to manufacture misoprostol and approved its use for 
gynecological conditions like cervical ripening, prevention of post partum 
hemorrhage and first trimester abortion with mifepristone50.  While in India, a 
combination of mifepristone and misoprostol is recommended for termination 
of early pregnancy up to 49 days/seven weeks from the last menstrual period 
(LMP); WHO recommends their use up to 63 days or nine weeks from LMP 
(WHO, 2003).13 
 
Mechanism of action 
Mifepristone is an anti-progestin, which stops the pregnancy from 
growing, detaches it from the lining of the uterus and softens the cervix.51,52 
Recommended Drug Protocol 
Day 1 200mg mifepristone orally. Anti D if Rh-ve 
Day 3 400 mcg misoprostol orally/vaginally. Analgesics 
Day 15 confirm completion of abortion by USG Contraceptive 
 
2. Contraceptive  
 
Mifepristone, a novel estrogen free contraceptive when administered in 
low doses daily (2 to 10mg), it inhibits ovulation, menstruation and 
significantly suppresses effects on the endometrium.30 However, due to 
continuation of variable degree of follicular development, unopposed 
estrogen can cause hyperplastic or malignant changes in the endometrium.  
But in 2003, Baird ST et al, in their study reported that mifepristone<10mg 
per day neither caused endometrial hyperplasia nor the significant effect on 
the HPA-axis.  Mifepristone also maintained bone density, lipids & sense of 
well being.  Mifepristone as a postcoital contraceptive inhibits ovulation, 
blocks implantation by causing a delay in maturation of endometrium and 
causes regression of the corpus luteum in the majority of women when given 
in the middle or late luteal phase.32,43,48  Two randomized trial have compared 
600 mg of mifepristone with the Yuzpe regimen.  In these trials single dose 
of 600mg of mifepristone given within 72 hours of unprotected intercourse 
was 100 percent effective as an emergency contraceptive.34 
 
3. Uterine myoma 
 
For safe and effective non-surgical treatment of symptomatic fibroids, 
high-dose progestin therapy and GnRh agonists have been shown to decrease 
overall uterine volume by 50 percent at the end of 3 months therapy.  So far 
no therapy has been used on a long term basis, therefore, the effect of medical 
therapy is temporary.  On a long term basis, mifepristone blocks progesterone 
dependent growth factors, reduces blood supply due to vascular changes and 
decreases inhibition of progesterone estrogen receptor gene transcription by 
the progesterone receptor - A isoform, these are some of the mechanisms 
causing the antiproliferative activity of mifepristone.  Mifepristone can be 
used in uterine fibroids as an alternative to GnRh anlogues in the preoperative 
application and if the safety of long term low dose mifepristone is 
established, perimenopausal women with large, symptomatic fibroid could 
avoid hysterectomies by using mifepristone till menopause.41 
 
4. Endometriosis 
Mifepristone through antioxidant property does not allow 
endometriosis to proliferate.  It also preserves follicular phase levels of 
estradiol 5mg dose does not stabilize the endometrium and hence needs a 
dose of 50mg daily.  However, the use of mifepristone for the treatment of 
endometriosis requires additional studies.42 
 
5. Ovarian Cancer  
Mifepristone inhibits ovarian cancer cells growth by inducing G1 cell 
cycle arrest and blocking the G1-S phase transition without causing cell 
death.  This growth arrest is observed by a decline in cyclin – dependent 
kinase 2 (cdk2) protein level and activity.44  In 2003, Xu M et al reported that 
ovarian cancer cells expressed glucocorticoid receptors.  Mifepristone may 
drive its anticancer action by binding to glucocorticoid receptors with an 
affinity similar to that for progesterone receptors and as an antioxidant to 
drive G1 arrest through a p53 independent p21.  In 2000, Rocereto TF et al in 
their small trial conducted with 44 patients suffering from recurrent epithelial 
ovarian cancer whose tumors had become resistant to standard chemotherapy, 
mifepristone administration showed desirable effects against some of the 
tumors.  Thus, mifepristone is a single agent potent blocker of ovarian cancer 
growth, however, the feasibility of using mifepristone to enhance the efficacy 
of conventional chemotherapy for ovarian cancer requires further 
investigations. 
 
6. Premenstrual Syndrome  
The sex steroid dependency of this disorder has been well established 
by the absence of PMS in castrated women and women treated with GnRH 
agonist analogues.  Because the main symptom complex occurs in the luteal 
phase when serum progesterone is at the highest level, it was proposed that an 
antiprogestin, such as RU 486, may be useful in treatment of PMS.40  Dosing 
schedules such as low dose daily administration to induce a acyclic pattern 
may yet prove to be efficacious in the treatment of PMS. 
 
7. Ectopic Pregnancy 
The role of antiprogestin in the medical therapy of ectopic pregnancy 
remains to be clearly defined.  Certainly, the timing, dosing, and efficacy of 
RU 486 treatment in this scenario awaits future studies. 
 
8. Abnormal Uterine Bleeding 
It has been suggested by some that antiprogestins may be useful in 
treatment of dysfunctional uterine bleeding.  No clinical experience in this 
venue has been published.  If adenomyosis is the etiology of menorrhagia, it 
may be expected that treatment with an antiprogestin may be useful. 
 
9. Breast Cancer  
It has been observed that estrogen and progesterone in low doses 
stimulates breast cancer growth but in high doses both inhibit breast cancer 
growth.  Tamoxifen, the antiestrogen, remains the first line therapy for 
advanced estrogen-receptor-positive tumor because of its efficacy, safety and 
convenience.  Antiestrogen (Tamoxifen) and antiprogestin produce tumor 
regression but either agent alone only produces tumor stasis.  Tamoxifen 
down regulates the estrogen receptor but it favors agonists activities and 
therefore up regulates the progesterone receptor.  Mifepristone down 
regulates both estrogen and the progesterone receptors.  The finding suggests 
that tamoxifen can not inhibit the progestin-mediated growth-stimulatory 
effects.  Thus, addition of mifepristone to tamoxifen effectively reestablishes 
tamoxifen growth inhibition.  It has been observed that eventually all 
advanced breast cancer become hormone independent and increasingly 
resistant to any subsequent therapy as a result there is limitation in potential 
utility of antiprogestin and other endocrine therapies for the treatment of 
advanced disease. 
 
10. Cushing’s Syndrome 
Chronic exposure to excessive corticosteroids in Cushing’s Syndrome 
leads to the development of multiple metabolic abnormalities such as glucose 
intolerance, dyslipidemia, hypertension, osteoporosis and weight gain. In 
2001, Dwight FM et al reported that extremely ill patient with Cushing’s 
syndrome, treated initially unsuccessfully by a combination of conventional 
surgical, medical and radiotherapeutic approaches responded extremely well 
up to 25mg/kg/day, long term mifepristone, glucocorticoid receptor 
antagonist therapy.  Treatment efficacy was confirmed by the normalization 
of all biochemical glucocorticoid-sensitive measurements, significant reversal 
of the patient’s heart failure, the resolution of the psychotic depression and 
usual return of his HPA axis to normal.25 
 
11. Meningioma  
Most meningiomas have no estrogen receptors but have substantial 
concentrations of progesterone receptors.  In patients with unresectable 
meningiomas, objective response and subjective improvement has been 
noted.29 
 
Contraindication 
Mifepristone is contraindicated in the presence of an intrauterine 
device (IUD), ectopic pregnancy, adrenal failure, hemorrhagic disorders, 
inherited porphyria and anticoagulant or long term corticosteroid therapy.  
 
Side Effects 
Side effects of short term use include abdominal pain, cramping, 
nausea, vomiting and headache which are dose and treatment duration 
dependant.  Long term administration of mifepristone is associated with 
adrenal insufficiency, low serum potassium levels, a slight increase in serum 
creatinine levels, moderate increase in hepatic enzymes and significant 
increase in thyrotrophins levels. 
 
Conclusion 
 The combination of mifepristone plus a prostaglandin has been 
approved for ending pregnancies of up to 49days.  The use of mifepristone 
plus an oral prostaglandin, presumably with fewer side effects,has improved 
the acceptability of this method for early first-trimester abortion over 
standard surgical procedure.Mifepristone has also been approved in France 
for the induction of labour in the event of fetal death Adequate clinical 
studies have demonstrated the safety and effectiveness of this drug and these 
studies support applications to regulatory authorities in other 
countries9.Cochrane review has justified further trials comparing mifepristone 
with the routine cervical ripening agents currently used53. 
PROSTAGLANDINS 
Structure  
 Prostaglandins are biological derivatives of 20 carbon polyunsaturated 
fatty acids that are released from cell membrane phospholipids.  The 
prostaglandins PGE2 and PGF2 alpha are widely used in obstetric practice. 
 
 There are no preformed stores of prostaglandin.  They are synthesized 
locally, in response to appropriate stimulus, at the rates governed by release 
of arachidonic acid from cell membrane by the action of lysosomal enzyme 
phospholipase A2, which is said to be the rate limiting step in prostaglandin 
biosynthesis. 
 
Free arachidonic acid enters the cyclo-oxygenase pathway and 
converted to prostaglandin, by the enzyme prostaglandin synthase.  In 
pregnant uterus of human being, free arachidonic acid is converted to 
prostaglandins in chorion leave and decidua vera, by prostaglandin synthetase 
specific activity, which is greatest in the amnion. 
 
 In the amnion and chorion, PGE2 is formed.  In decidua vera, both 
PGE2 and F2 alpha are formed.  The fetal membranes and decidua vera are 
proved to be the site of synthesis of both arachidonic acid and prostaglandins 
in amniotic fluid. The half-life of primary prostaglandins is about five 
minutes while that of the major metabolite is 8 minutes.  The lung is the 
major site of metabolism of prostaglandins, other sites being the liver and 
kidney. 
 
Pharmacological actions 
 Prostaglandins act on almost every other tissue in the body.  Some of 
the best known actions are (a) stimulation of smooth muscle leading to either 
relaxation depending upon the receptors involved (b) changes in the cervical 
tissue (c) inhibition of gastric acid secretion and cytoprotection (d) inhibition 
and induction of platelet aggregation (e) increase in vascular permeability (f) 
thermoregulation (g) modification of steroidogenesis in the adrenals and 
gonads (h) inhibition of hormone induced lipolysis (i) release of 
neurotransmitters in the peripheral nervous system and the potentiation of 
action of biogenic amines. 
 
 However, the most potent action of prostaglandins is their ability to 
stimulate smooth muscles of the uterus, gut and vasculature.  Unlike 
oxytocin, which is relatively ineffective in early pregnancy prostaglandins, 
are potent stimulators of uterine myometrium in all stages of pregnancy. 
 
 Uses of prostagandins in obstetrics include induction of abortion, 
termination of molar pregnancy, induction of labour, cervical ripening prior 
to induction of labour and abortion, acceleration of labour, management of 
atonic postpartum haemorrhage. 
 
 Muscle physiology consists of three important concepts: phasic 
contraction, tonic tension and relaxation.  Phasic contraction is intermittent 
and may last for a short or a long period of time, whereas tonic tension is 
fairly constant lasting for prolonged periods.  At the myometrial cellular 
level, prostaglandins have been found to induce both phasic contractions as 
well as tonic tension with superimposed phasic contractions (Chamley and 
Parkington 1984).  In practical terms, they increase both the resting tone of 
the uterine myometrium as well as the amplitude and duration of myometrial 
contractions. 
 
 On a molecular level, phasic contractions are due to the influx of 
sodium ions into the myometrial cell, whereas tonic tension is due the 
increased availability of intracellular calcium.  Both these processes are 
affected by prostaglandins (Reiner and Marshall 1976).  
 
 Prostaglandins also induce the formation of gap junctions between the 
myometrial cells, which help in the development of coordinated myometrial 
action, giving the advantages of a functional syncytium. 
 
 There is also a differential response according to the type of 
prostaglandins.  PGE2 metabolites peak prior to the onset of established 
labour, whereas PGF2alpha metabolites peak during labour and correlate 
directly with the duration of labour.  PGE2 has a predominant effect on the 
cervix, whereas PGF2alpha on the myometrium. 
Contraindications 
 
(a) Hypersensitivity to the compounds  
(b) Bronchial asthma  
 
Advantages 
(a) It has got powerful oxytocic effects, irrespective of the period of 
pregnancy.  (b) As such it can be used independently especially in induction 
of abortion with success.  (c) It is useful drug not only in induction but also 
for acceleration of labour.  (d) it has no antidiuretic effect. 
 
Disadvantages 
(a) It is costly (b) Unpleasant side-effects caused by its stimulatory effects on 
the smooth muscles, which however subside easily due to its rapid 
metabolism (c) When used as an abortifacient, extensive cervical laceration 
may occur (d) The hyperactivity of the uterus if occurs during induction may 
continue for a variable period.  
 
Side effects 
(a) Nausea, vomiting and diarrhea are common.  (b) Cramping pain of uterine 
origin related to the degree of uterine activity.  (c) Unduly forceful uterine 
contractions.  (d) Anaphylaxis.  
 
 
Oxytocin 
 
 The word ‘oxytocin’ means “Quick birth”.  The structure of oxytocin 
was determined by Du vigneaud in 1950. 
 
 Oxytocin, an octapeptide which is secreted in a pulsatile manner is a 
neurohormone originating in the hypothalamus and secreted by the posterior 
lobe of pituitary gland.  The half life is 10-12 minutes. The metabolic 
clearance rate is similar for men, pregnant women and non pregnant women.  
20-27 m1/kg/minute.  Recent study shows that 40 minutes are required for 
any particular dose of oxytocin to reach a steady state plasma concentration.3 
 
 The sensitivity of uterus to oxytocin increases as pregnancy progresses 
due to increase in oxytocin receptors in the myometrium and decidua.  
Oxytocin has direct stimulatory effects on the myometrium and also 
stimulates decidual prostaglandin production. The direct effect of oxytocin on 
myometrium is mediated by polyphosphoinositide hydrolysis with production 
of inositol phosphates that act as a second messenger and lead to the 
mobilization of interacellular calcium ion. The principles of current clinical 
usage of intravenous oxytocin, are based on the classic studies of Turnbull 
and Anderson (1968).  
 
 Oxytocin is known to be a very potent uterotonic, causing uterine 
contractions in a sensitized uterus.  The infusion of oxytocin is relatively 
ineffective in inducing labour in human pregnancies, except for dose near 
term.  Oxytocin is effective, only in those patients in whom preparation of the 
uterus for active labour is already completed.  The plasma concentration of 
oxytocin in pregnant women is 2-10mcg/ml. 
 
Advantages 
 It is cost effective, relatively safe, the dosage can be adjusted and 
titrated according to the needs in a particular case, when combined with 
amniotomy induction delivery interval is very short, labour gets established 
earlier. 
 
Disadvantages 
 Patient has to be confined to bed, in large doses it produces water 
intoxication, there are chances of hyperbilirubinemia, when given in higher 
doses, rarely it can cause rupture of uterus in multigravida and coronary 
insufficiency, and the incidence of PPH in induced labour is greater. 
Hyperstimulation, late deceleration of FHR can occur.5 
Table.2.2: RCOG guidelines for induction of labour (2001)1 
 
Time after 
starting 
(min) 
Oxytocin dose 
(mu/min) 
Volume infused  
(ml/hour) 
  
Dilution 30 IU 
Oxytocin in 500 ml 
normal saline 
Dilution 10 IU 
Oxytocin in 500 ml 
normal saline 
0 1 1 3 
30 2 2 6 
60 4 4 12 
90 8 8 24 
120 12 12 36 
150 16 16 48 
180 20 20 60 
210 24 24 72 
240 28 28 84 
270 32 32 96 
 
 
 
 
 
 
MATERIALS AND 
METHODS  
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
Selection of cases 
 This comparative study done to compare the efficacy of oral 
mifepristone and endocervical PGE2 gel as preinduction cervical ripening 
agents in term gestation and prolonged pregnancies was done in 
uncomplicated antenatal women who had clear indication for induction of 
labour, admitted in antenatal ward and labour ward at Government Kilpauk 
Medical Hospital, Chennai.  100 antenatal women were selected for study 50 
women received oral mifepristone 200mg and 50 women received 
endocervical PGE2 gel 0.5mg. 
 
This comparative study was done after getting clearance from ethical 
committee of Government Kilpauk medical college, Chennai. 
 
Inclusion Criteria 
1. Singleton pregnancy in cephalic presentation. 
2. Post dated uncomplicated pregnancy. 
3. Term uncomplicated pregnancies with unfavourable cervix.  (Bishop -
score < 4) 
4. Intra uterine fetal death. 
5. Congenitally anomalous babies. 
6. Term or post term pregnancies with no contraindications for vaginal 
delivery. 
7. No contraindications for prostaglandins or mifepristone. 
8. Primigravida less than  35 years and uncomplicated multigravida up to 
three pregnancies. 
9. Intact membranes during the time of induction. 
 
Exclusion Criteria 
1. Premature rupture of membranes. 
2. Malpresentations. 
3. Cephalopelvic disproportion. 
4. Bad obstetric history or history of previous abortions. 
5. Previous history of caesarean section or any uterine surgery. 
6. Associated medical complications. 
7. Multiple pregnancy. 
8. Elderly primigravida (age > 35 years). 
9. Oligohydramnios. 
10. Rh Negative mother. 
11. Placental complications like abruption or placenta praevia. 
12. Abnormal fetal heart rate patterns. 
13. IUGR 
14. Parity > 3 
15. Active herpes infection. 
16. Contra indication for prostaglandins. 
17. Chorioamnionitis 
18. Any febrile morbidity. 
 
On admission, a detailed history, and complete general and obstetric 
examination was carried out.  Vaginal examination was done under strict 
aseptic precautions and the cervical status, fetal station were assessed.  
Gestational age calculated by Naegle’s rule and a routine obstetric scan for 
fetal maturity and well-being was done. Once the inclusion criteria were 
fulfilled and cephalopelvicdisproportion was ruled out, the patient was 
prepared and transferred to the labour ward.  Indication for induction was 
noted after reaffirming that there was no contraindication for induction. 
 
Informed Consent 
 A detailed written informed consent was obtained from the participant 
and her relatives.  The following were addressed in the consent form.  
Indication for induction of labour, drug to be administered with its dosage 
and mode of administration, side effect of the drug, risks associated with the 
administration of these drugs and if complications arise, alternative mode of 
termination were all discussed. 
 
 
Treatment Schedule 
Group – I 
 50 pregnant women were given tablet mifepristone 200mg orally on 
day1. They were observed for maternal vitals, uterine activity bleeding or 
draining pv and fetal heart rate. After the wait period of 24 hours or when the 
Bishop score was ≥ 6, when the cervical dilatation was > 2cm, or when the 
membranes ruptured or when the patient was well in labour whichever is 
earlier labour was accelerated with oxytocin drip. 
 
Group – II 
 50 pregnant women pregnant  were instilled endocervical PGE2 gel 
0.5mg on day 1. They were observed for maternal vitals,uterine 
activity,bleeding or draining pv and fetal heart rate.  After the wait period of 
6 hours or when the Bishop score was ≥ 6,  when the cervical dilatation was  
>2cm, or when the membranes ruptured or when the patient was well in 
labour whichever is earlier labour was accelerated with oxytocin drip. 
 
Monitoring of the patients 
 Maternal vitals, uterine activity and fetal heart rate were monitored 
clinically.  Partogram was maintained for all patients and used to record all 
the clinical events during the course of labour.  A watch for the rupture of 
membranes was done. If membranes not ruptured ARM was done at 3cm 
cervical dilatation. Pervaginal examination was done if there was rupture of 
membranes or once in 2 hours in active phase of labour.  The pulse rate, 
blood pressure, temperature and urine output were recorded . Delivery 
particulars duration of each stage of labour blood loss at  third stage of labour 
and baby particulars were recorded.Mother and baby were observed for 
postnatal complications if any. 
 
          Data were analysed and all the values were expressed as mean ± 
standard deviation or as percentages.  Statistical comparison were performed 
by students paired and unpaired t-test and chi-square test. Statistically 
significant difference (P<0.05). 
 
The efficacy was assessed by the following criteria: 
1. Favourability of Bishop score at 24 hrs. 
2. The need of oxytocin for augmentation. 
3.  Duration of  I,  II and III stage of labour and blood loss. 
4. Drug administration to delivery interval. 
5. The mode of delivery. 
6. Cesarean section rate. 
7. The 5 minute Apgar score, neonatal complications and incidence of 
neonatal mortality. 
8. Maternal complications. 
  
Success of induction was assessed by the following criteria: 
1. Patients who delivered vaginally within 48 hours of the start of 
induction. 
2. Bishop score of ≥ 6  at the end of 24 hours 
 
Failure of induction was assessed by the following criteria: 
1. Patients who delivered vaginally after 48 hours of start of induction. 
2. Patients who underwent caesarean section. 
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ANALYSIS OF THE RESULTS  
 
AGE AND PARITY DISTRIBUTION 
Group - I Group - II Age group 
(Years) Primi Multi Primi Multi 
≤ 20 8 (16 %) 1 (2 %) 8 (16 %) 2 (4 %) 
21 – 29 17 (34 %) 21 (42 %) 18 (36 %) 19 (38 %) 
≥ 30 1 (2 %) 2 (4 %) 1 (2 %) 2 (4 %) 
Total 26 (52 %) 24 (48 %) 27 (54 %) 23 (46 %) 
 
 
 
 
Age and parity distribution of women included in this study were 
comparable in both mifepristone and PGE2 gel group. 
 INDICATION FOR INDUCTION OF LABOUR 
Indication Group - I Group - II 
Prolonged Pregnancy 49 (98 %) 49 (98 %) 
IUD 0 1 (2 %) 
Congenital anomaly 1 (2%) 0 
Total 50 (100 %) 23 (46 %) 
 
 
 
 
The major indication for induction was prolonged pregnancy 49 (98 %) 
in each group and 1 (2 %) was induced for term IUD in mifepristone group 
and 1 (2 %) was induced for congenital anomaly in term baby in PGE2 gel 
group 
 
BISHOP SCORE AT THE START OF STUDY 
Group – I Group – II 
Score 
Primi Multi Primi Multi 
0 1 (2 %) - - - 
1 7 (14 %) 1 (2 %) 8 (16 %) 5 (10 %) 
2 16 (32 %) 21 (42 %) 18 (36 %)  13 (26 %) 
3 2 (4 %) 2 (4 %) 1 (2 %) 5 (10 %) 
 
 
  
All the mothers in both groups had initial Bishop Score of 0 to 3 before 
preinduction cervical ripening. 
 
FAVOURABILITY OF BISHOP SCORE 
Group – I Group – II Score at 
augmen
tation Primi Multi Total Primi Multi Total 
< 6 5 (10 %) 0 5 (10%) 13 (26 %) 9 (18 %) 22 (44%)
≥ 6 21 (42 %) 24 (48 %) 45 (90%) 14 (28 %) 14 (28 %) 28 (56%)
 
 
 
 
 
FAVOURABILITY OF BISHOP SCORE 
 
 Group Mean Std. Deviation 
Std. Error 
mean 
Group – 1 1.8800 0.55842 0.07897 
Bishop score start 
Group – II 1.8600 0.60643 0.08576 
Group – 1 6.8800 1.46580 0.20730 Bishop score at 
Augmentation Group – II 5.5000 2.29685 0.32482 
Group – 1 5.0000 1.55183 0.21946 
Bishop score difference  
Group – II 3.6400 2.14533 0.30340 
 
 
 
 Mean increase in Bishop score in mifepristone group is 5 whereas 3.6 
in PGE2 gel group.   
• P - Value for Bishop score at start 0.864 which is not significant. 
• P - Value for Bishop score at augmentation 0.001 which is significant.  
• P - Value for Bishop score difference 0.000 which is significant. 
AUGMENTATION WITH OXYTOCIN 
Group - I Group - II 
Augmentation 
Primi Multi Total Primi Multi Total 
Required 
20  
(40 %) 
13  
(26 %) 
33 
(66%) 
19  
(38 %) 
20  
(40 %) 
39 
(78%) 
Not required 
6  
(12 %) 
11  
(22 %) 
17 
(34%) 
8  
(16 %) 
3  
(6 %) 
11 
(22%) 
 
 
 In the mifepristone group among the 6 primigravida who were not in 
need of oxtocin augmentation 4 (8%) had vaginal delivery within 24 hours of 
oral mifepristone administration.  Shortest drug administration to delivery 
interval was 12 hours and 5 minutes.  Among the 11 multigravida who were 
not in need of oxytocin augmentation in the mifepristone group 9 (18%) had 
vaginal delivery with in 24 hours of oral mifepristone, of which 4 (8%) had 
delivery within 10 hours.  Shortest drug administration to delivery interval 
was 5 hours 54 minutes. 
 
 Whereas in PGE2 gel group 11 antenatal women which includes 8 
primigravida and 3 multigravida who were not in need of oxytocin 
augmentation were those delivered by cesarean section.  In other words in 
PGE2 gel group all women who had vaginal delivery were in need of 
oxytocin augmentation. 
 
MEAN DURATION OF LABOUR 
 Group Mean Std. Deviation 
Std. Error 
mean 
P value  
Group – 1 6.8867 2.12457 0.31671 Duration of 1st 
Stage (Hour) Group – 2 6.8618 1.41495 0.22954 
0.951 
(NS) 
Group – 1 22.4222 5.19829 0.77492 Duration of 2nd 
Stage (Mints) Group – 2 26.9474 6.40501 1.03903 
0.001 
(S) 
Group – 1 4.0659 1.20309 0.18137 Duration of 3rd 
Stage (Mints) Group – 2 5.4408 1.30596 0.21185 
0.000 
(S) 
Group -1 18.7341 10.04693 1.48134 
DD intervial  
Group -2 11.4784 3.85563 0.62547 
0.000 
(S) 
 
 
 
Duration of II and III stage of labour were shorter in mifepristone 
group with statistical significance. Duration of I stage \shorter in PGE2 gel 
group which is not statistically significant Drug administration to delivery 
interval shorter with PGE2 gel group with statistical significance. 
 
Group –I  ‘P’ Value    Group –II ‘P’ Value 
I Stage    0.001 (Significant )   0.609 (Not Significant) 
11 Stage   0.192 (Not Significant)   0.655 (Not Significant) 
III Stage  0.005 (Significant)    0.169(Not Significant) 
DD interval 0.031 (Significant)    0.098(Not Significant) 
 
Statistically significant shorter duration of I and III stage of labour in 
multigravda in miferpristone group whereas no statistical difference in 
duration of labour among primigravida and multigravida in PGE2 gel group.    
 
Group - I Group - II 
Stages of Labour 
Primi Multi Primi Multi 
I – Stage (hours) 7.8542 5.7810 6.9816 6.7421 
II – Stage (Minutes) 23.3750 21.3333 27.4211 26.4737 
III – Stage (Minutes) 4.5435 3.5429 5.7342 5.1474 
Drug administration 
to delivery interval 
(hours) 
21.6292 15.2876 12.5142 10.4426 
MODE OF DELIVERY 
Group - I Group - II 
Mode of Delivery 
Primi Multi Total Primi Multi Total 
Labour naturale 
22  
(44 %) 
21 
 (42 %) 
43  
(86%) 
18 
 (36 %) 
18  
(36 %) 
36 
(72%) 
Outlet forceps 
delivery 
1  
(2 %) 
- 
1 
 (2%) 
- 
1  
(2 %) 
1  
(2 %) 
LSCS 
3  
(6 %) 
3  
(6%) 
6  
(12%) 
9  
(18 %) 
3 
 (6 %) 
12  
(24 %) 
Spontaneous 
expulsion of fetus 
- - - 
1  
(2 %) 
- 
1  
(2 %) 
Total 
26  
(52 %) 
24  
(48 %) 
50  
(100%) 
27  
(54 %) 
23 
 (46 %) 
50  
(100 %) 
 
 
 Cesarean section rate was higher in PGE2 gel group which was 24 % 
when compared to mifepristone group in which it was 12 %. 
INDICATION FOR LSCS 
Group - I Group - II 
Indication for LSCS 
Primi Multi Primi Multi 
Failed induction 1 (2 %) - 3 (6 %) 1 (2%)  
Fetal distress 2 (4 %) 3 (6 %) 6 (12%) 2 (4%) 
Total 3 (6 %) 3 (6 %) 9 (18 %) 3 (6 %) 
 
In the mifepristione group 3 (6%)  primigravida were delivered by 
cesarean section of which 1 (2%) was done for failed induction and 2 (4%) 
were done for fetal distress whereas in multigravida 3 (6%) were delivered by 
cesarean section for fetal distress. 
 
 In the PGE2 gel group among 9 (18%) primigravida delivered by 
cesarean 3 (6%) were done for failed induction and 6 (12%) were done for 
fetal distress  whereas in multigravida 1(2%) were done for failed induction  
and 2 (4%) were done for fetal distress. 
 
MEAN BLOOD LOSS 
Blood Loss Group - I Group - II 
Mean Blood loss (ml) 248  368 
Standard Deviation  160.66190 222.63725 
Standard Error mean 22.72102 31.48566 
 
 
          P value : 0.03  (significant) 
 Mean blood loss in mifepristone group was less when compared to 
PGE2 gel In PGE2 gel group 1 (2%) Primigravida had atonic PPH – blood 
loss of 1250ml which was controlled with uterotonics. 
 
 
 
 
MATERNAL COMPLICATIONS 
Maternal Complications Group - I Group - II 
Fever 2 (4 %) 5 (10 %) 
GI symptoms 3 (6 %) 3 (6 %) 
Abdominal cramps 4 (8 %) - 
Uterine contractile 
abnormalities 
- - 
PP H - 1 (2 %) 
Puerperal sepsis - - 
 
Maternal Complications were similar in both groups. 
  
NEONATAL COMPLICATIONS 
Neonatal Complications Group - I Group - II 
Respiratory distress 2 (4 %) 3 (6 %) 
Meconium aspiration 
syndrome  
2 (4 %) 5 (10 %) 
Transient tachypnoea of 
newborn 
1 (2 %) - 
APGAR <7 7 (14 %) 7 (14 %) 
NICU admission 5 (10 %) 9 (18 %) 
 
 
 NICU admission was 18% in PGE2 gel as compared to 10% in 
mifepristone group.  In PGE2 gel group  one neonate was admitted for low 
birth weight. 
 
 Apgar Score at 1 minute and 5 minute were similar in both groups. 7 
(14%) neonates in each group had Apgar Score < 7 at 5 minutes following 
birth. 
 
  
 
 
 
 
DISCUSSION 
 
 
 
 
 
DISCUSSION 
Table 1 
Sl. 
No. Study Year Dosage Schedule Control 
Wait 
period 
1. Wing DA at al 
2002 
(180) 
200mg of mifepristone oral 
dose followed by intravaginal 
misoprostol 25 microgr  ams 
every 4th hourly or IV 
oxytocin.17 
Placebo 24 Hrs 
2. LiL et al 1996 
150 or 200mg mifepristone in 
the 1st 2 or 3 days & on 4th day 
misoprostol was added 
successively in 100-300 micro 
gram dosage.14 
- 3 Days 
3. SuH et al 
1996 
 
(124) 
50mg mifepristone 12th hourly 
for 2 days followed by 
prostaglandin or oxytocin.15 
- 48 Hrs 
4. Frydam R et al 
1992 
(120) 
200mg mifepristone on day 1 
and 2 followed by 
augmentation with 
prostaglandin on day 4.10 
Placebo 4 Days 
5. Giacolone PL et al 1992 
400mg of mifepristone as a 
single single oral dose.16 
Placebo  48 Hrs 
6. Elliot et al 
1998 
(83) 
50-200mg mifepristone as a 
single oral dose.19 
Placebo 
24Hrs 
interval 
for 72 
hrs 
7. Padayachi T et al 1989 
400mg mifepristone as a single 
oral dose.20 
- 72 Hrs 
8. This study  2010 
200mg mifepristone as a single 
oral dose. 
PGE2 24 Hrs 
 In this study mifepristone given as 200mg single dose orally and 
observation period of 24 hours similar to the wing DA etal and Elliot et al 
study in which mifepristone were compared with placebo whereas PGE2 gel 
in this study.  
Table - 2 
No Study Year Need for augmentation 
1. LiL et al 1996 80% 
2. SuH et al 1996 Decreased 
3. Frydman R et al  1992 decreased 
4. Wing DA et al 2002 67% 
5. This study  2010 66% 
 
 In this study 66% required oxytocin, which was consistent with prior 
studies. 
 In this study mean duration of first stage was less than 8 hours and 
second stage duration was less than 30 minutes.  These results were 
consistent with WHO standards. 
 In this study 36 (72%) women 32% primigravida and 40% 
multigravida delivered vaginally within 24 hours and totally 44 (88%) 
women 46% primigravida and 42% multigravida delivered vaginally within 
48 hours which was consistent with Wing DA et al study. 
 
 
 Table - 3 
Sl. 
No. Study Year Incidence of vaginal delivery 
1. LiL et al 1996 80.88% 
2. SuH et al 1996 22.58% (vs 4.84% of control group) 
3. Giacalone PL et al 1992 80.5% 
4. Wing DA et al 2002 87.5% 
5. This study  2010 88% 
 
In this study vaginal delivery rate was 88% (46% primigravida and 
42% multigraavida) the results were consistent with above mentioned studies. 
In this study intrapartum complications like hypertonus, tachysystole 
or hyperstimulation were not encountered, which was consistent with Wing 
DA et al study. Meconium passage was encountered in 4% and NICU 
admission was 10%. 
 
In this study the success of induction was vaginal delivery within 48 
hours.  Success rate was 88% which was consistent with 87.5% success rate 
in wing DA et al study and 80.5% in Giacalone et al study. 
 
In this study success of induction in relation to change to favourable 
Bishop score of 6 or more was seen in 90% (42% in primigravida and 48% in 
multigravida) which was consistent with Frydman et al study, Giacalone et al 
study, Wing DA et al study and Elliot et al study. 
In this study failed induction in terms of cesarean section or vaginal 
delivery after 48 hours of ripening was seen in 12% among which 1 
primigravida underwent cesarean section for failed induction.  These results 
were consistent with Giacalone et al study,  Elliot et al study and wing DA et 
al study in which failed induction rate was 9.2%. 
 
Mifepristone is administered orally which is very convenient and 
antenatal mothers can be ambulant when compared to cumbersome PGE2 gel 
administration which has to be instilled endocervically with strict asepsis by 
technically skilled personnel and needs observation in left lateral position. 
 
Mifepristone is stored at room temperature whereas PGE2 gel storage 
needs cold chain maintenance the cost of mifepristone is comparable to PGE2 
gel.  Further need of oxytocin for augmentation is very much reduced with 
mifepristone when compared to PGE2 gel. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
 
 The safety and efficacy of oral mifepristone as a preinduction cervical 
ripening agent is assessed in this study and compared with PGE2 gel.  100 
antenatal mothers admitted at Government Kilpauk Medical Hospital, who 
needed elective induction, satisfying the inclusion criteria were recruited into 
two groups and each were given oral mifepristone 200mg or endocervical 
PGE2 gel 0.5mg for cervical ripening and augmented with oxytocin.  This 
study documents the success of induction, details of parturition, maternal and 
neonatal outcome. 
 
This study revealed that  
 
 Mothers in both groups had Bishop score of 0 to 3 at the start of 
study.  90% (42% primigravida and 48% multigravida) had 
favourable Bishop score in mifepristone group whereas only 56% 
(28% primigravida and 28% multigrovida) in PGE2 gel group. 
 
 Oxytocin augmentation not needed in 26% (8% primigrovida and 
18% multigravida) in mifepristone group who had vaginal delivery 
whereas all mothers who had vaginal delivery in PGE2 gel group 
required oxytocin. 
 
 Duration of II and III stage of labour shorter in miferpristone group . 
 Cesarean section rate was 12% in mifepristone group whereas 24% in 
PGE2 gel group. 
 Blood loss was less in mifepristone group. 
 Neonatal complications  and neonatal admissions were lesser in 
mifepristone group. 
 Drug administration to delivery interval shorter with PGE2 group. 
 Maternal complications were similar in both groups. 
 The outcome of induction in this study reveals that the mifepristone 
was successful in 88% in achieving vaginal delivery whereas PGE2 
gel was successful in 76%. 
 
  
 
 
 
 
CONCLUSION 
 
 
 
 
 
CONCLUSION 
 
 This study reveals that oral mifepristone is very safe and an effective 
drug for preinduction cervical ripening.  It has an added advantage of ease of 
administration, better patient compliance and acceptance, reduced oxytocin 
requirement, shorter duration of II, III stages of labour, less blood loss with 
an overall success rate of 88%.  The drug has no untoward side effects on 
uterine contraction and no major maternal complications. This drug has safe 
nenatal outcome.  
        This drug is more effective in multigravida when compared to 
primigravida Hence mifepristone offers advantages over PGE2 gel which is 
currently used for preinduction cervical ripening.  
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PROFORMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PROFORMA 
 
Name:    Age    DOA: 
         DOD: 
 
Address:    IP.No    L.M.P: 
 
     SES    E.D.D: 
 
HISTORY: 
 History of Presenting complaints   Booked Case: Yes/No. 
 
 Obstetric History  Gr  P  L  A 
 Menstrual History  
 Past Medical / Surgical History 
 Personal History 
 Family History 
 
GENERAL PHYSICAL EXAMINATION 
Height    Weight   BMI 
Pallor    Edema    
Pulse     BP    RR  Temperature 
CVS    RS    Breast Thyroid 
 
Per Abdomen – Uterine Size    Activity 
  - Lie     Presentation  Position 
  - FHR 
 Per Speculum 
Per Vaginum -   Cx Dilatation  Position Consistency 
    Effacement 
    Integrity of membranes 
    Presentation and Station 
    Pelvic Assessment 
 
INVESTIGATIONS 
1. Hb% 
2. Urine-albumin 
Sugar 
Deposits 
3. Bloodgroup&Rh typing 
4. Blood-urea 
-Sugar 
5. Serum creatinine 
6. HIV, VDRL, HBSAG 
7. Obstetric scan – single, live/dead, fetus 
- Cardiac activity&fetal movements 
- B.P.D- cms  weeks days 
- F.L -  cms  weeks days 
- Placenta-fundal anterior/posterior 
- Grade  maturity 
- Liquor  adequate/not 
- Obvious congenital abnormalities 
Bishop score on admission- 
Indication for induction- 
Date and time of induction- 
 
Bishop score at time of induction- 
Drug used for preinduction ripening-PGE2 gel/ 
  - mifepristone 
Wait period after induction 
Bishop score at time of augmentation 
Augmentation with oxytocin- yes/no 
Dosage needed 
 
DURATION OF LABOUR 
First stage  (Hrs) 
Second stage (Mts) 
Third stage (Mts)  
NATURE OF DELIVERY 
Insrumental delivery 
Labour 
Natural/labour natural 
with episiotomy 
Outlet 
forceps 
Low 
midcavity 
forceps 
Vacuum 
delivery 
Lscs 
Indication 
     
 
Amount of blood loss at III stage 
Drug administration to delivery interval  
Complications-Maternal 
Nausea/vomiting/diarrhea 
Headache/hyperthermia/fever 
Abdominal cramps 
Chorioamnionitis/endometritis/puerperal sepsis, 
Uterine contraction abnormalities- 
Tachysystole/hypertonus/Hyperstimulation. 
Any Treatment Given 
Intrapartum &Fetal Complications 
1. Fetal heart rate abnormalities 
2. Meconium passage-thin/thick 
 
BABY 
Birth weight 
Apgar 1’   5’ 
Congenital anomalies if any 
Neonatal resuscitation 
Neonatal admissions 
Fetal complications-Meconium aspiration syndrome 
                                    -Hyperbilirubinemia 
                                    -Others 
  
 
A
t start
 A
t 
A
ugm
n.
I Stage 
(H
r)
II Stage 
(M
ts)
M
aternal
Fetal
I" 5"
1 Maheswari 21 2501 B IV P PP 2 6 Yes 5 9 25 20.02 LN 5.5 300 Nausea - 3.22 6 8 No
2 Revathi 23 2539 B V P PP 2 8 Yes 5 6.3 30 8.25 LN 6 250 fever - 2.88 7 8 No
3 Lily 23 2497 B IV M PP 3 6 Yes 2.5 7 20 9.3 LN 3 300 - - 4 6 8 No
4 Umamaheswari 19 2563 B IV P PP 2 4 Yes 5 8.3 35 15.1 LN 5 300 - - 3 7 8 No
5 Vanitha 24 3800 B IV M PP 2 6 Yes 2.5 6 28 9.25 LN 7 350 - - 3.3 7 8 No
6 Seetha 26 4260 B IV M PP 2 6 Yes 2.5 6 23 8.49 LN 6 300 - - 2.5 7 8 No
7 Madhavi 21 4370 B V P PP 2 2 No - - - - LSCS - 750 - - 2.93 5 7 No
8 Saraswathy 24 4376 B IV P pp 1 4 Yes 10 7.3 22 15.13 LN 6 200 - - 2.45 6 8 No
9 Vanishree 26 4390 B V P IUD 2 4 Yes 5 5.15 30 14.45 SP. EXPLN 5 150 - - 3.19 - - No
10 Jenifer 24 4510 B V M PP 1 8 Yes 2.5 7.3 20 8 LN 5 300 fever - 2.3 7 8 No
11 Buvaneswari 25 4577 B IV P PP 2 6 Yes 5 8.3 40 11.43 LN 5 200 - - 2.25 7 8 No
12 Bagyalaksmi 19 4051 B IV P PP 2 8 Yes 5 6 25 8 LN 5.4 250 - - 2.75 6 8 No
13 Reka 18 6294 B V P PP 2 4 Yes 5 7.3 23 15.07 LN 8 200 - - 2.18 5 7 No
Indication for induction
D
.D
 Interval (H
r)
N
IC
U
 A
dm
ission
MASTER CHART
Sl. N
o.
N
am
e
SES
Prim
i/M
ulti
B
ishop's 
score 
B
lood Loss (M
L)
A
pgar
C
om
plication
B
.w
t (K
g)
III Stage D
uration (M
ts)
A
ge
PG E2 GEL
A
ugm
entation w
ith 
oxytocin
A
m
ount of O
xytocin 
(U
nits)
M
ode of D
elivery
IP.N
o
D
uration
B
ooked /U
nbooked
14 Murugmmal 21 4231 B V P PP 1 3 No - - - - LSCS - 700 - FHA MSL 3.01 4 6 Yes
15 Faritha 27 4469 B IV M PP 2 6 Yes 2.5 8.3 30 12.15 LN 5.15 300 - - 3.2 6 8 No
16 swathi 21 6640 B IV P PP 1 8 Yes 5 5.3 22 7.19 LN 5 250 - - 3.5 4 6 Yes
17 Revathy 21 7622 B IV M PP 2 4 Yes 2.5 6 22 14.16 LN 3.5 300 - - 3.09 6 7 No
18 Sathya 28 7726 B IV M PP 2 8 Yes 2.5 5 30 8.45 LN 5 300 - - 3.05 7 8 No
19 Uvarani 24 7743 B V P PP 1 9 Yes 5 5.3 25 7.33 LN 5 250 - - 1.3 4 5 Yes
20 Jeyakodi 21 7855 B V P PP 2 6 Yes 5 6.5 35 10.35 LN 7 300 - - 2.43 6 7 No
21 Alamelu 25 7885 B IV P PP 2 8 Yes 5 6 20 8.32 LN 5 150 - - 3.61 6 8 No
22 Shameem 19 7801 B V P PP 2 8 Yes 5 6 20 9.09 LN 5.3 250 - - 2.98 6 8 No
23 Tamilselvi 19 7757 B IV P PP 2 8 Yes 5 6.3 22 9.46 LN 5.15 250 - - 2.25 6 8 No
24 Prema 23 7857 B IV M PP 2 9 Yes 2.5 6 25 8.2 LN 5.5 250 - - 2.75 8 9 No
25 Indumathi 30 7770 B IV M PP 2 9 Yes 2.5 5 28 8.01 LN 8 250 - - 2.65 6 8 No
26 Lakshmi 22 7963 B V M PP 2 8 Yes 2.5 6 23 9.56 LN 5 150 - FHA 2.4 5 6 Yes
27 Vijayalakshmi 35 5724 B V P PP 2 2 No - - - - LSCS - 750 fever - 3.35 7 8 No
28 Buveneswari 20 7395 B IV P PP 1 3 No - - - - LSCS - 1250 PPH FHA MSL 3 4 6 Yes
29 Muthulakshmi 25 7817 B V P PP 2 4 No - - - - LSCS - 750 - FHA MSL 2 6 8 Yes
30 Reka 23 7840 B IV M PP 2 2 No - - - - LSCS - 600 - FHA 3.25 7 8 No
31 Banu 30 7826 B IV P PP 1 3 No - - - - LSCS - 600 - FHA MSL 2.5 5 7 No
32 Savithri 27 7710 B IV P PP 2 2 No - - - - LSCS - 750 - FHA MSL 2.5 6 8 No
33 Eswari 25 7983 B IV M PP 1 2 No - - - - LSCS - 600 - - 3.02 6 8 No
34 Radhika 32 8019 B IV M PP 1 1 No - - - - LSCS - 700 - - 3.3 6 8 No
35 Sumathi 33 8183 B V M PP 2 4 Yes 2.5 8.3 35 14.15 LN 7.1 250 - - 2.3 5 7 No
36 Bagyalaksmi 20 8184 B IV P PP 1 6 Yes 2.5 10 42 18.15 LN 8 300 - - 2.69 7 8 No
37 Nadhiya 19 8195 B IV P PP 2 6 Yes 5 8.3 38 13.28 LN 7.15 250 fever - 2.87 7 8 No
38 Sumathi 22 8156 B IV M PP 1 4 Yes 2.5 7.3 26 10.1 LN 6.5 300 - - 2.355 6 8 No
39 Bavani 25 8162 B V P PP 2 4 Yes 2.5 9 20 24.51 LN 5.15 250 Vomiting - 2.9 6 8 No
40 Prema 19 8190 B V M PP 3 8 Yes 2.5 6 22 14.35 LN 4.3 300 - - 2.74 6 8 No
41 Gracy 22 8168 B V M PP 3 8 Yes 2.5 4.3 28 8.49 OUTLET.F.D 4 500 - MSL 3.6 4 6 Yes
42 Sasikala 25 8169 B IV P PP 1 4 No - - - - LSCS - 600 - FHA MSL 2.9 5 7 Yes
43 Shameem 26 8178 B IV M PP 2 6 Yes 5 - - - LSCS - 500 - FHA MSL 2.9 4 6 Yes
44 Chilia 22 8144 B V M PP 2 4 Yes 2.5 8.3 35 14.15 LN 6.3 250 fever - 3.2 6 8 No
45 Vidhya 21 8156 B V M PP 1 4 Yes 2.5 7.3 26 10.1 LN 6 200 - - 3.16 6 8 No
46 Brinda 23 8166 B IV P PP 3 8 Yes 5 6 22 14.15 LN 4.15 250 - - 2.85 7 8 No
47 Neela 26 8175 B IV P PP 2 4 Yes 2.5 6.3 25 12.49 LN 6.15 300 - - 3 6 8 No
48 Mari 24 8185 B V M PP 3 8 Yes 2.5 10 40 12.05 LN 4.3 300 - - 3.15 5 7 No
49 Sudha 20 8196 B IV M PP 3 8 Yes 2.5 8 20 9.3 LN 3 150 - - 2.81 6 8 No
50 Kavya 26 8205 B IV M PP 2 4 Yes 2.5 6 22 10.15 LN 3.15 150 Vomiting - 2.65 6 8 No
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1 Amudha 22 768 B IV P PP 2 4 Yes 5 9 35 28.35 LN 7 250 - - 2.92 5 6 No
2 Suganya 20 780 UB IV P ANOMALOUS BABY 0 6 Yes 5 7.3 25 23.3 LN 5.3 150 - - 1.87 - -6 No
3 kavitha 21 841 B IV M PP 2 6 No - - - - LSCS - 650 - FHAMSL 3 4 6 Yes
4 Nalini 22 890 B IV P PP 2 6 Yes 5 9.3 30 24.2 LN 5.3 300 Nausea - 2.25 7 8 No
5 Mythili 20 1897 B IV P PP 2 8 Yes 5 8 28 12.35 LN 5 150 - - 2.23 6 8 No
6 Selvarani 26 3246 B V M PP 2 6 Yes 5 - - - LSCS - 600 - FHAMSL 3.4 4 6 Yes
7 Divyamohan 23 3264 B IV P PP 1 8 No - - - - LSCS - 500 - FHA 3.34 5 6 yes
8 Devakumari 24 4054 B IV M PP 2 8 No - - - - LSCS - 650 - FHA 3.34 5 7 No
9 Vishalakshi 29 4530 B IV M PP 2 8 No - 6.5 20 7.1 LN 3 150 - - 2.65 5 7 No
10 Uma 27 4304 B V M PP 1 6 Yes 2.5 9 25 22.55 LN 3.45 150 - - 2.63 7 8 No
11 Jeyalakshmi 23 4614 B IV M PP 3 6 Yes 2.5 6.3 20 20.52 LN 5 150 - - 3 5 8 No
12 Nithya 20 4649 B V P PP 3 8 Yes 5 11 20 16.1 LN 8 150 - - 3.45 5 7 No
13 Chitra 27 4644 B V M PP 2 6 No 2.5 9 23 27.3 LN 5 150 Abd. Cramps - 3.2 7 8 No
14 Kamala 25 2560 B IV M PP 3 6 Yes - 4.15 17 19.53 LN 3 150 - - 2.84 6 8 No
15 Kamala 28 4405 B V P PP 2 4 Yes 5 7.2 20 28.53 LN 3 400 Abd. Cramps - 2.43 6 8 No
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16 Tamilselvi 21 6101 B IV P PP 2 8 No - 8.2 36 15.01 LN 5.3 150 - - 2.9 5 7 No
17 Kavipriya 24 2225 B V M PP 2 8 Yes 2.5 5.3 21 16.1 LN 5.2 250 - - 2.8 6 8 No
18 Selvarani 21 2221 B IV M PP 2 6 Yes 2.5 5.3 25 20.04 LN 3 200 - - 3.14 6 8 No
19 Indirani 26 2249 B IV P PP 2 8 Yes 5 6 25 14.15 LN 5.2 250 - - 3 6 8 No
20 Meena 28 2462 B IV M PP 2 8 Yes 2.5 4.5 22 11.15 LN 3.5 150 - - 3 6 8 No
21 Jeyamani 20 3379 B V M PP 2 6 Yes 2.5 5.3 20 26.44 LN 3.15 150 Nausea - 3.16 6 8 No
22 Chitra 26 2930 B IV M PP 2 8 No - 5.3 30 8.53 LN 3.5 150 - - 2.7 6 8 No
23 Rathi 23 3002 B IV P PP 1 8 Yes 5 5.3 20 9.2 LN 5 250 Abd. Cramps - 2.8 6 8 No
24 Brinda 23 3136 B IV M PP 2 8 Yes 2.5 6 22 12.1 LN 3 200 - - 3.5 6 8 No
25 Devi 21 3218 B IV P PP 2 4 Yes 5 8.5 25 29.59 LN 3 150 - - 3 6 8 No
26 Nithya 30 3220 B V M PP 2 8 Yes 2.5 5.15 18 16.25 LN 4.15 150 - - 3.2 6 8 No
27 Selvalakshmi 21 3316 B IV P PP 1 6 Yes 5 10.5 25 31 LN 3.5 250 - 3.2 6 8 No
28 Nazeema 24 3260 B IV P PP 2 6 Yes 5 8 22 18.25 LN 3.3 150 - - 3 6 8 No
29 Latha 20 3261 B V P PP 1 8 Yes 5 6.3 21 17.1 LN 3.5 250 - - 3.16 6 8 No
30 Devi 22 6484 B IV P PP 3 6 Yes 5 6 22 20.14 LN 3.3 100 Abd. Cramps - 2.095 5 7 No
31 Parvathy 30 6488 B IV M PP 2 6 Yes 2.5 6.3 23 21.04 LN 3 100 - - 2.8 6 8 No
32 Chitra 23 6616 B IV P PP 2 8 Yes 5 5.3 20 6.26 LN 5 150 Fever - 2.82 6 8 No
33 Kumari 27 6636 B IV M PP 2 8 No - 3 20 6.2 LN 4 100 - - 2.965 5 7 No
34 Chitra 20 6634 B IV P PP 2 8 Yes 5 8.5 20 10.4 LN 3.5 150 - - 2.32 7 7 No
35 Renuka 26 6579 B IV P PP 1 6 Yes 5 8 23 31.5 LN 5 150 - - 2.49 6 7 No
36 shenbagam 24 7727 B IV M PP 2 8 Yes 2.5 6 20 16.52 LN 3 150 - - 2.85 6 8 No
37 Dhanalakshmi 34 7708 B V M PP 2 8 Yes 2.5 6 20 10.55 LN 3.3 200 Fever - 2.5 7 8 No
38 Bavani 24 7797 B IV M PP 2 8 No - 4.3 20 5.54 LN 3.5 300 - - 3 6 8 No
39 Bagyalakshmi 32 7810 B IV M PP 2 8 No - 6 20 12.05 LN 3 200 - - 2.58 6 8 No
40 Devi 23 7822 B V M PP 2 8 No - 6 20 12.3 LN 3.15 200 - - 3 6 8 No
41 Vedavalli 18 7836 B IV P PP 2 8 Yes 5 8.3 26 14.3 LN 3 150 - - 1.85 5 8 No
42 Rajaveni 32 7872 B IV P PP 2 6 No - 8 26 21.27 LN 6 300 - - 2.88 6 8 No
43 Bavani 19 7899 B IV P PP 1 8 No - 6 20 16.1 LN 5 500 - - 2.4 6 8 No
44 Sureka 21 7903 B V P PP 2 8 Yes 5 6.3 20 15.45 LN 3 150 Vomiting - 2.74 6 8 No
45 Kalyani 22 7911 B IV P PP 2 8 Yes 5 8 30 15.13 Outlet 5 250 - - 3.2 6 8 No
46 Sumalatha 23 7923 B IV P PP 2 8 No - 4.5 20 12.5 LN 3.3 250 - - 2.85 6 8 No
47 Hemalatha 22 7930 B V P PP 2 2 No - - - - LSCS - 600 - TTN 3.1 5 6 Yes
48 Thenmozhi 24 7965 B IV M PP 2 6 No - 6 20 19.2 LN 3 200 - - 2.6 6 8 No
49 Yamuna 27 8009 B IV M PP 2 8 No - 6 22 10.03 LN 3.5 200 - - 3.05 5 7 No
50 Patchaiammal 20 8015 B IV P PP 1 4 Yes 5 - - - LSCS - 750 - FHA 2.5 5 6 Yes
- Socioeconomic status - Intra uterine death
IP No. - In Patient Number - Primigravida - Drug administration to delivery interval
B - Booked - Multigravida - Birth weight
UB - Unbooked - Prolonged pregnancy - Neonatal intensive care unit
TTN- Transient tachypnoea of newborn FHA - LN - Labour naturale 
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Fevet - 1
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FHA - 1
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Yes - 1
No - 2
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